Close

Cyclacel Pharma (CYCC) Reports Selection of Recommended Phase 2 Dose for CYC065

August 7, 2017 7:16 AM EDT Send to a Friend
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login